SANTA CLARA, Calif.–(BUSINESS WIRE)– Heart Beam, Inc.. (NASDAQ: BEAT), a cardiac technology company that developed the first and only 3D vector ECG platform for anytime, anywhere heart attack detection, will hold a conference call on Thursday, November 10, 2022 at 4 p.m. 30:30 a.m. Eastern Time to discuss its results for the third quarter ended September 30, 2022, and will review recent announcements, ongoing initiatives and key milestones for 2022 and planned for 2023. A press release detailing these results will be published before the call.
HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the conference call, followed by a Q&A. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the Investor Relations section of the Company’s website. here.
To access the call, please use the following information:
A telephone replay will be available approximately two hours after the call and will continue through February 10, 2023 by dialing 1-844-512-2921 from the United States or 1-412-317-6671 from international destinations and by entering the replay PIN. : 7787050. The replay can also be viewed via the webcast link above and the presentation used in the call will be available in the company’s investor relations section. here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a heart technology company that has developed the first and only 3D vector ECG platform for anytime, anywhere heart attack detection. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to quickly and easily determine if symptoms are due to a heart attack, so care can be expedited. , if necessary. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to aid in remote heart attack detection . HeartBeam AIMI and AIMIGo have not yet been cleared by the United States Food and Drug Administration (FDA) for marketing in the United States or other geographies. For more information, visit HeartBeam.com.
All statements in this release that are not based on historical fact are “forward-looking statements.” Although management has based the forward-looking statements included in this release on its current expectations, the information on which these expectations were based may change. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those contained in the forward-looking statements due to a variety of factors, including the risks and uncertainties described in the Risk Factors and in the management report of the financial situation. The Trading Status and Results sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider these risks and uncertainties when evaluating our forward-looking statements. We caution readers not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by federal securities laws, we disclaim any obligation or undertaking to release any updates or revisions to any forward-looking statements contained herein (or elsewhere) to reflect any changes in our expectations with respect thereto. or any change of events. , conditions or circumstances on which such statement is based.